Case Challenge: Incorporate Real-World Evidence in the Management of Hormone Receptor-Positive Metastatic Breast CancerPremiere Date: Monday, April 27, 2020
This activity offers CE credit for:%>
- Physicians (CME)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Tuesday, April 27, 2021
Note: Credit Is No Longer Available
|Martine J. Piccart, MD, PhD
Honorary Professor of Oncology
Universite Libre de Bruxelles (ULB)
Jules Bordet Institute
The use of real-world data (RWD) to generate real-world evidence (RWE) that reflects the complexity of usual treatment patterns of oncology care and clinical outcomes, and represents a broader spectrum of patients, can provide treatment benefit estimates outside the well-defined framework of trial settings. The potential for RWE is particularly significant in the oncology setting, where combination therapy offers great benefits for patients. Cyclin-dependent kinase (CDK) 4 and 6 inhibitors in combination with endocrine therapy (ET) have emerged as a standard-of-care treatment for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC), and RWE, when effectively deployed, can help determine treatment effects in the real world.
In this CME Outfitters BriefCase, expert faculty discuss the challenges and nuances of a case scenario as well as practical strategies for incorporating RWE into daily clinical practice in MBC.
At the end of this CE activity, participants should be able to:
- Assess evidence on real-world, clinical experience for CDK 4/6 inhibitors in MBC.
- Integrate RWE into daily practice and decision-making in the MBC setting.
Supported by an educational grant from Pfizer Inc.
Oncologists, hematologists, oncology nurses, oncology pharmacists, nurse practitioners, pathologists, and surgeons
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Bethesda, Maryland, USA. Please retain your certificate as proof of completion.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Piccart reports that she receives grants to her institute from AstraZeneca; Eli Lilly and Company; Genentech, Inc./Roche; Merck Sharp & Dohme (MSD); Novartis; Pfizer Inc.; Radius Health, Inc.; Servier; and Synthon. She is on the advisory committee as a Scientific Board Member for Oncolytics Biotech, Inc. She is a consultant for AstraZeneca; Camel-IDS; Crescendo Biologics; Debiopharm; Eli Lilly and Company; F. Hoffman-La Roche Ltd; G1 Therapeutics, Inc.; Genentech, Inc.; Huya Bioscience International; Immunomedics; MSD; Novartis; Odonate Therapeutics, Inc.; PeriphaGen, Inc.; Pfizer Inc.; Seattle Genetics, Inc.; and The Menarini Group.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Poshala Tish Aluwihare, PhD (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).